Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time
- 363 Downloads
Injecting drug users (IDUs) are the main at-risk population for hepatitis C virus (HCV) transmission. We studied HCV infection, risk factors, and genotype distribution in relation to the year of first injection among Iranian IDUs. Of a total of 126 specimens positive for HCV antibody, 93 (74 %) had detectible HCV RNA, and the NS5B gene was sequenced for 83, with genotype 3a (n = 48, 58 %) being predominant, followed by 1a (n = 35, 42 %). Tattooing was an independent predictor for HCV infection. No significant difference was found between HCV genotypes and IDU characteristics. Although there was no change in the distribution of prevalent genotypes before and after 1997, a slight variation in the prevalence was observed (p = 0.71). The difference in the prevalence of subtypes 1a and 3a (9.1 % in the period 1984-1996 and 18.2 % in the period 1997-2009) during 25 years was 9.1 %. These findings indicate a high prevalence of HCV infection among Iranian IDUs and highlights HCV-3a as the most prevalent subtype for the past 25 years. Harm-reduction strategies appear to be the most important measures to reduce the transmission of HCV in Iran.
KeywordsThalassemia Syringe Sharing Iranian IDUs Average Evolutionary Distance
We would like to thank Dr. Ali Malakzadeh and his colleagues at West Health Center for their cooperation in sample collection. We thank Dr. Mehrdad Pedram (Dept. of Biotechnology and Medical Genetics, Zanjan University of Medical Sciences) for his careful editing of the manuscript and helpful comments.
- 2.Zamani S, Radfar R, Nematollahi P, Fadaie R, Meshkati M, Mortazavi S, Sedaghat A, Ono-Kihara M, Kihara M (2010) Prevalence of HCV /HIV /HBV infections and drug–related risk behaviours amongst IDUs recruited through peer–driven sampling in Iran. Int J Drug policy 21:493–500PubMedCrossRefGoogle Scholar
- 4.Zali MR, Nowroozi A, Amir-rasooly H, Darvishi M (1998) Prevalence of anti HCV antibody and routes of hematological transmission addicts of Ghasr prison [in Persian]. Pajouhesh 22:26–32Google Scholar
- 6.Mohamad Alizadeh AH, Alavian SM, Jafari K, Yazdi N (2005) Prevalence of HCV infection and its related risk factors in drug abuser prisoners in Hamedan –Iran. World J Gastroenterol 11:4085–4089Google Scholar
- 7.Asgari F, Gooya MM, Mohammad K, Fotouhi A, Yousefi A (2008) Hepatitis C virus infection among Iranian prisoners and its relation with addiction, 2001–2005 [in Persian]. Hakim 11:1–8Google Scholar
- 8.Khani M, Vakili M-M (2003) Prevalence and risk factors of HIV, Hepatitis B virus and Hepatitis C virus infections in Drug addicts among Zanjan prisoners. Arch Iranian Med 6:1–4Google Scholar
- 10.Mohtasham Amiri Z, Rezvani M, Jafari shakib R, Jafari shakib A (2007) Prevalence of HCV infection and risk factors of drug using prisoners in Guilan province. EMHJ 13:250–256Google Scholar
- 20.Paintsil E, Verevochkin SV, Dukhovlinova E, Niccolai L, Barbour R, White E, Toussova OV, Alexander L, Kozlov AP, Heimer R (2009) Hepatitis C virus infection among drug injectors in St. Petersburg, Russia: social and molecular epidemiology of an endemic infection. NIH 104:1881–1890Google Scholar
- 21.Demetriou VL, van de Vijver DA, Hezka J, Kostrikis LG; Cyprus IVDU Network, Kostrikis LG (2010) Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. J Med Virol 82:263–270Google Scholar
- 23.Zali MR, Aghazadeh R, Noroozi A, Amirrasooli H (2001) Anti-HCV antibody among Iranian IV drug users: is it a serious problem? Arch Iranian Med 4:115–119Google Scholar